JP2016506931A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016506931A5 JP2016506931A5 JP2015555360A JP2015555360A JP2016506931A5 JP 2016506931 A5 JP2016506931 A5 JP 2016506931A5 JP 2015555360 A JP2015555360 A JP 2015555360A JP 2015555360 A JP2015555360 A JP 2015555360A JP 2016506931 A5 JP2016506931 A5 JP 2016506931A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- buffer
- agent
- present
- pharmacologically active
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims description 47
- 239000000872 buffer Substances 0.000 claims description 16
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical group CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 11
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 11
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 11
- 208000035475 disorder Diseases 0.000 claims description 10
- 239000012929 tonicity agent Substances 0.000 claims description 9
- 208000010412 Glaucoma Diseases 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 5
- 239000007951 isotonicity adjuster Substances 0.000 claims description 5
- BBMHARZCALWXSL-UHFFFAOYSA-M sodium dihydrogenphosphate monohydrate Chemical compound O.[Na+].OP(O)([O-])=O BBMHARZCALWXSL-UHFFFAOYSA-M 0.000 claims description 5
- 239000000739 antihistaminic agent Substances 0.000 claims description 4
- 239000003246 corticosteroid Substances 0.000 claims description 4
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 claims description 3
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 230000001387 anti-histamine Effects 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 150000002978 peroxides Chemical class 0.000 claims description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000008363 phosphate buffer Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 11
- 150000003839 salts Chemical class 0.000 description 6
- 150000001204 N-oxides Chemical class 0.000 description 5
- 208000030533 eye disease Diseases 0.000 description 5
- 229940002612 prodrug Drugs 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- 125000005456 glyceride group Chemical group 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 241001303601 Rosacea Species 0.000 description 2
- 206010046851 Uveitis Diseases 0.000 description 2
- 208000002205 allergic conjunctivitis Diseases 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000024998 atopic conjunctivitis Diseases 0.000 description 2
- 208000002780 macular degeneration Diseases 0.000 description 2
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 201000004700 rosacea Diseases 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- BHIZVZJETFVJMJ-UHFFFAOYSA-N 2-hydroxypropyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCC(C)O BHIZVZJETFVJMJ-UHFFFAOYSA-N 0.000 description 1
- GHHURQMJLARIDK-UHFFFAOYSA-N 2-hydroxypropyl octanoate Chemical compound CCCCCCCC(=O)OCC(C)O GHHURQMJLARIDK-UHFFFAOYSA-N 0.000 description 1
- 239000004381 Choline salt Substances 0.000 description 1
- 208000003556 Dry Eye Syndromes Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940125715 antihistaminic agent Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical group C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 235000019417 choline salt Nutrition 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 229940026235 propylene glycol monolaurate Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361756306P | 2013-01-24 | 2013-01-24 | |
| US61/756,306 | 2013-01-24 | ||
| PCT/US2014/013036 WO2014117010A2 (en) | 2013-01-24 | 2014-01-24 | Composition for ophthalmic administration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016506931A JP2016506931A (ja) | 2016-03-07 |
| JP2016506931A5 true JP2016506931A5 (enExample) | 2017-03-02 |
| JP6351629B2 JP6351629B2 (ja) | 2018-07-04 |
Family
ID=50102221
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555360A Expired - Fee Related JP6351629B2 (ja) | 2013-01-24 | 2014-01-24 | 点眼用組成物 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20140206708A1 (enExample) |
| EP (1) | EP2948130B1 (enExample) |
| JP (1) | JP6351629B2 (enExample) |
| CA (1) | CA2898644A1 (enExample) |
| WO (1) | WO2014117010A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9463201B2 (en) | 2014-10-19 | 2016-10-11 | M.G. Therapeutics Ltd | Compositions and methods for the treatment of meibomian gland dysfunction |
| MA44676A (fr) | 2016-04-14 | 2019-02-20 | Azura Ophthalmics Ltd | Compositions de disulfure de sélénium destinées à être utilisées dans le traitement du dysfonctionnement de la glande de meibomius |
| CN107805212B (zh) * | 2017-11-03 | 2021-08-20 | 宿迁德威化工股份有限公司 | 一种2-甲基-5-氨基苯磺酰胺的制备方法 |
| EP4087655A4 (en) | 2020-01-10 | 2024-02-21 | Azura Ophthalmics Ltd | INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1227128A (en) * | 1916-11-06 | 1917-05-22 | Ohio Blower Company | Conveying mechanism. |
| ZA815175B (en) * | 1980-08-01 | 1982-09-29 | Smith & Nephew Ass | Pharmaceutical composition |
| HU207222B (en) * | 1990-02-15 | 1993-03-29 | Chinoin Gyogyszer Es Vegyeszet | Process for producing eyedrops containing primycin |
| BR9711406A (pt) * | 1996-09-20 | 1999-08-17 | Bausch & Lomb | Sistema e m-todo para reumidifica-Æo de lentes de contato e alivio da secura dos olhos |
| AU2001278779A1 (en) * | 2000-08-25 | 2002-03-04 | Senju Pharmaceutical Co. Ltd. | Aqueous suspension preparations |
| WO2002085248A2 (en) * | 2001-04-23 | 2002-10-31 | Board Of Regents The University Of Texas System | Prostanoids augment ocular drug penetration |
| KR20090053892A (ko) * | 2006-07-25 | 2009-05-28 | 오스모티카 코프. | 점안액 |
| JP2011525388A (ja) * | 2008-06-24 | 2011-09-22 | キューエルティー プラグ デリバリー，インク． | 緑内障の併用治療 |
| JP6100997B2 (ja) * | 2008-11-04 | 2017-03-22 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | 酸化感受性ポリマーのための包装材としてのコンポジットフィルムの使用、酸化感受性ポリマーの包装方法、及び該コンポジットフィルムを含有する包装体 |
| KR101740076B1 (ko) * | 2009-07-28 | 2017-06-08 | 리겔 파마슈티칼스, 인크. | Ｊａｋ 경로의 억제를 위한 조성물 및 방법 |
| US20120022149A1 (en) * | 2010-07-21 | 2012-01-26 | Chowhan Masood A | Pharmaceutical composition with enhanced solubility characteristics |
-
2014
- 2014-01-24 US US14/163,948 patent/US20140206708A1/en not_active Abandoned
- 2014-01-24 WO PCT/US2014/013036 patent/WO2014117010A2/en not_active Ceased
- 2014-01-24 JP JP2015555360A patent/JP6351629B2/ja not_active Expired - Fee Related
- 2014-01-24 CA CA2898644A patent/CA2898644A1/en not_active Abandoned
- 2014-01-24 EP EP14704453.1A patent/EP2948130B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010266120B2 (en) | Compositions comprising finafloxacin and methods for treating ophthalmic, otic, or nasal infections | |
| JP2011527339A5 (enExample) | ||
| JP2009524692A (ja) | ドライアイのための処方物および方法 | |
| JP2015007136A5 (enExample) | ||
| JP2015110672A (ja) | ビマトプロストおよびブリモニジンの固定用量の組み合わせ | |
| JP2012520882A5 (enExample) | ||
| JP2013500977A5 (enExample) | ||
| JP2021102626A (ja) | ブリモニジン及びチモロールの固定用量合剤 | |
| JP2011093923A (ja) | 点眼剤 | |
| JP2015528501A5 (enExample) | ||
| TW202031263A (zh) | 抑制軟性隱形眼鏡變質之眼科用組成物 | |
| JP2016506931A5 (enExample) | ||
| CN107708738A (zh) | 含有柠檬酸酯的贮库制剂 | |
| WO2016171152A1 (ja) | 角膜障害の治療剤、改善剤または予防剤 | |
| AR106691A1 (es) | Formulaciones oftálmicas de escualamina | |
| JP7599838B2 (ja) | エピナスチン又はその塩を含有する水性医薬組成物 | |
| JP4980226B2 (ja) | 眼科用組成物及びその使用方法 | |
| Romanowski et al. | Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit model of intrastromal keratitis | |
| JP2011144111A (ja) | 軸性近視の予防または治療剤 | |
| EP2143422A1 (en) | Ophthalmic compositions containing gemifloxacin for the treatment of ocular infections | |
| TWI816660B (zh) | 噻托銨用於製造預防近視、治療近視及/或預防近視增長之點眼劑之用途 | |
| JP6474913B2 (ja) | 外用剤 | |
| WO2016020408A2 (en) | Compounds for preventing ototoxicity | |
| US20240261291A1 (en) | Ophthalmic Compositions and/or Methods for Presbyopia, Mydriasis and/or Ocular Discomfort Management | |
| JP7417531B2 (ja) | 選択的ｓｙｋ阻害剤の使用方法および医薬組成物 |